On April 26, the "Seventh Qihuang Forum" hosted by the Chinese Society of Traditional Chinese Medicine was held in Beijing. The 2024 Ten Academic Progress of Traditional Chinese Medicine was released at the meeting. "Traditional Chinese medicine's chain of cardiovascular events has obtained high-level evidence support" is on the list. The project explains the unique advantages and efficacy of traditional Chinese medicine in the prevention and treatment of cardiovascular events, and provides a research paradigm for the study of traditional Chinese medicine's major diseases.

It is reported that the Chinese Society of Traditional Chinese Medicine organized and carried out the selection of ten academic progress of traditional Chinese medicine in 2024. This year's selection work adheres to the "four aspects", highlights exploration and forward-looking, innovative and breakthrough, and highlights the new discoveries, new laws, new ideas, new methods, new technologies, new products, etc. that have been achieved in the fields of clinical research, basic research and applied research in traditional Chinese medicine, and to meet clinical needs, answer scientific questions, and promote industrial development. It reflects the value of this year's research results in improving the mechanism for inheritance, innovation and development of traditional Chinese medicine and promoting the high-quality development of traditional Chinese medicine. After dynamic collection, preliminary review, final review and other work procedures, the ten academic progress of traditional Chinese medicine in 2024 will be determined.

The cardiovascular event chain refers to the myocardial infarction caused by high-risk factors, which later develop into arrhythmia, heart failure and death. With the support of the national key R&D plan, Professor Jia Zhenhua from Hebei Yiling Hospital, joined forces with Academician Tong Xiaolin, Professor Yang Yuejin, Professor Li Xinli, Professor Huang He and Professor Bu Peili's team to carry out a systematic study on the prevention and treatment of cardiovascular event chains in traditional Chinese medicine.

Through clinical studies of 889 patients with abnormal glucose tolerance in metabolic syndrome, Jinlida Granules can systematically regulate metabolic abnormalities, protect blood vessels, delay arteriosclerosis, and significantly reduce the risk of diabetes; Through clinical studies of 220 patients with coronary vulnerable plaques, Tongxinluo Capsules can increase the thickness of the fiber cap, stabilize vulnerable plaques, improve angina pectoris, and reduce the trend of event occurrence; Through clinical studies of the effects of recurrence after catheter ablation in 920 patients with atrial fibrillation, Shensongyangxin Capsules can reduce the risk of atrial fibrillation recurrence within one year after ablation, reduce the load on atrial fibrillation, and improve the quality of life; Through clinical studies of 3,119 patients with chronic heart failure, Qifeng Qiangxin Capsules can improve the prognosis of patients with heart failure, reduce the risk of cardiovascular death and worsening heart failure. Through basic research and network integration analysis, the efficacy mechanism and scientific connotation of preventing upstream factors, treating current lesions, and controlling downstream transmission are explained.

The research results are published in journals such as Nature Medicine, JAMA Internal Medicine and European Heart Journal in 2024. This progress explains the unique advantages and efficacy of traditional Chinese medicine in preventing and treating cardiovascular event chains, and provides a research paradigm for traditional Chinese medicine to prevent and treat major diseases.

It is reported that the relevant achievements of traditional Chinese medicine in preventing and treating cardiovascular events have made important breakthroughs in the process of modernization of traditional Chinese medicine. It has won the first prize of Science and Technology of the Chinese Society of Integrated Traditional Chinese and Western Medicine, won the 2024 health innovation practice case, and was selected as the "Pilot Technology" category of typical cases in the field of traditional Chinese medicine in 2024 "Science and Innovation China"; it was selected as the typical case of landmark scientific and technological achievements of the 2024 World Traditional Chinese Medicine Conference; related drugs, Qiefu, Qiangxin, Jinlida, etc., have entered the authoritative guides such as the "Guidelines for Diagnosis and Treatment of Heart Failure" and "Guidelines for the Prevention and Treatment of Diabetes in China".

[Editor in charge: Sun Hui]